Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (CLLS) has released its monthly share capital and voting rights report as of March 31, 2025. The company reported a total of 100,290,078 shares in its capital structure, with 89,046,759 total voting rights. This disclosure complies with Article 223-16 of the General Regulation of the French financial markets authority for companies listed on Euronext Growth.
Cellectis (CLLS) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs and strategic partnerships. The company maintains a strong cash position of $264 million, providing runway into mid-2027.
Key pipeline updates include:
- UCART22 Phase 1 data and development strategy expected in Q3 2025, with FDA granting Orphan Drug and Rare Pediatric Disease Designations
- UCART20x22 Phase 1 study in NHL ongoing with readout expected late 2025
- Three active programs in collaboration with AstraZeneca
Notable corporate developments include AstraZeneca's $140 million additional equity investment and the completion of European Investment Bank financing drawdown of €40 million. The company has deprioritized UCART123 development to focus on BALLI-01 and NATHALI-01 studies.
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing platforms for cell and gene therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for March 13, 2025, after US market close.
The company will host an investor conference call and webcast on March 14, 2025, at 8:00 AM ET / 1:00 PM CET to discuss the financial results and provide business updates. Investors can access the call through domestic (+1-800-225-9448) or international (+1-203-518-9708) dial-in numbers using Conference ID: CLLS24.
Cellectis (CLLS) has released its monthly share capital and voting rights report as required by Article 223-16 of the French financial markets authority's General Regulation. The company's shares are listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS) presented its 'Smart CAR T' strategy at AACR-IO 2025, showcasing an innovative approach to enhance CAR T cell efficacy against solid tumors. The presentation focused on a technique using interleukin 2 (IL-2) to improve treatment outcomes.
The company's research demonstrates that their TALEN® gene editing technology enables CAR T cells to express a CAR-inducible IL-2 variant (IL-2v) immunocytokine, which is activated by tumor-specific signals within the solid tumor microenvironment (TME). This engineered IL-2v boosts anti-tumor activity both in vitro and in vivo, while minimizing systemic toxicity by anchoring to the FAP protein present in the TME.
The development aims to improve CAR T-cell expansion and persistence without the toxicity risks typically associated with high-dose IL-2 administration, potentially representing a safer and more effective treatment approach for solid tumors.
Cellectis has released its monthly share capital and voting rights update as of January 31, 2025, in accordance with Article 223-16 of the French financial markets authority's General Regulation. The company reported a total of 100,093,873 shares in capital and 88,660,571 voting rights. This information was disclosed for the Euronext Growth market, where Cellectis trades under the ISIN code FR0010425595.
Cellectis has released its monthly share capital and voting rights report as of December 31, 2024. The company reported a total of 100,093,873 shares in the capital and 88,660,539 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, as the company is listed on Euronext Growth under ISIN code FR0010425595.
Cellectis (NASDAQ: CLLS) has drawn down the final €5 million tranche (Tranche C) from its €40 million credit facility agreement with the European Investment Bank (EIB). The disbursement is expected by December 18, 2024, completing the full €40 million facility established on December 28, 2022.
The funds will support the development of Cellectis' allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As part of the agreement, Cellectis issued 611,426 warrants to the EIB, each convertible into one ordinary share at €1.70 per share, representing approximately 0.6% of the company's outstanding shares. Tranche C has a six-year maturity with a 6% annual interest rate, capitalized annually and payable at maturity.
Cellectis has released its monthly share capital and voting rights information as of November 30, 2024. The company reported a total of 100,093,873 shares in the capital and 88,576,206 voting rights. This disclosure is made in accordance with Article 223-16 of the General Regulation of the French financial markets authority, with the company's shares listed on Euronext Growth under ISIN code FR0010425595.
Cellectis has reported its monthly share capital and voting rights information as of October 31, 2024. The company disclosed a total of 100,093,873 shares in the capital and 88,569,210 voting rights. This disclosure is made in compliance with Article 223-16 of the General Regulation of the French financial markets authority for its listing on Euronext Growth under ISIN code FR0010425595.